NO323129B1 - Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner, fremgangsmate for frmstilling derav, deres anvendelse som lipasehemmere samt legemiddel inneholdende en slik forbindelse. - Google Patents
Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner, fremgangsmate for frmstilling derav, deres anvendelse som lipasehemmere samt legemiddel inneholdende en slik forbindelse. Download PDFInfo
- Publication number
- NO323129B1 NO323129B1 NO20021007A NO20021007A NO323129B1 NO 323129 B1 NO323129 B1 NO 323129B1 NO 20021007 A NO20021007 A NO 20021007A NO 20021007 A NO20021007 A NO 20021007A NO 323129 B1 NO323129 B1 NO 323129B1
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- substituted
- phenyl
- oxdiazol
- optionally
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 229940127470 Lipase Inhibitors Drugs 0.000 title 1
- -1 pyrrolidino, piperidino, morpholino, thiomorpholino Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
- 102100026020 Hormone-sensitive lipase Human genes 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 102000000019 Sterol Esterase Human genes 0.000 claims description 5
- 108010055297 Sterol Esterase Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 claims description 3
- 150000002429 hydrazines Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000872 2-diethylaminoethoxy group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000007710 freezing Methods 0.000 description 41
- 230000008014 freezing Effects 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 229950000964 pepstatin Drugs 0.000 description 4
- 108010091212 pepstatin Proteins 0.000 description 4
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- VKFUXPVYODLUCH-IUPFWZBJSA-N (z)-2,3-bis[(z)-octadec-9-enyl]henicos-12-ene-1,2,3-triol Chemical compound CCCCCCCC\C=C/CCCCCCCCC(O)(CO)C(O)(CCCCCCCC\C=C/CCCCCCCC)CCCCCCCC\C=C/CCCCCCCC VKFUXPVYODLUCH-IUPFWZBJSA-N 0.000 description 3
- 108010087765 Antipain Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101100421709 Schistosoma mansoni SM21.7 gene Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- DGBIMUZIXHVUEH-UHFFFAOYSA-N (4-morpholin-4-ylsulfonylphenyl)hydrazine Chemical compound C1=CC(NN)=CC=C1S(=O)(=O)N1CCOCC1 DGBIMUZIXHVUEH-UHFFFAOYSA-N 0.000 description 2
- CXMSKBSKYRABJH-UHFFFAOYSA-N 1-nitro-4-(3,3,5,5-tetramethylcyclohexyl)oxybenzene Chemical compound C1C(C)(C)CC(C)(C)CC1OC1=CC=C([N+]([O-])=O)C=C1 CXMSKBSKYRABJH-UHFFFAOYSA-N 0.000 description 2
- LDBBCISSYGDVIH-UHFFFAOYSA-N 4-(4-fluorophenyl)sulfonylmorpholine Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCOCC1 LDBBCISSYGDVIH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BFCFYVKQTRLZHA-UHFFFAOYSA-N 1-chloro-2-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC=C1Cl BFCFYVKQTRLZHA-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- PIQXIIHPQBQVTP-UHFFFAOYSA-N 3,3,5,5-tetramethylcyclohexan-1-ol Chemical compound CC1(C)CC(O)CC(C)(C)C1 PIQXIIHPQBQVTP-UHFFFAOYSA-N 0.000 description 1
- LOFTYCJRFKIKFR-UHFFFAOYSA-N 3-(3-phenoxyphenyl)-5-propan-2-yloxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC(C)C)=NN1C1=CC=CC(OC=2C=CC=CC=2)=C1 LOFTYCJRFKIKFR-UHFFFAOYSA-N 0.000 description 1
- SIJSIGJILCLFFL-UHFFFAOYSA-N 3-(4-cyclohexylphenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(C2CCCCC2)C=C1 SIJSIGJILCLFFL-UHFFFAOYSA-N 0.000 description 1
- BKLNUMKZTRTDRT-UHFFFAOYSA-N 3-[3-[2-(diethylamino)ethoxy]phenyl]-5-ethoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C1=CC=CC(OCCN(CC)CC)=C1 BKLNUMKZTRTDRT-UHFFFAOYSA-N 0.000 description 1
- SNVZDWOBITWIFS-UHFFFAOYSA-N 3-[4-(4-chlorophenoxy)phenyl]-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 SNVZDWOBITWIFS-UHFFFAOYSA-N 0.000 description 1
- UMDLPUVGLXTSBX-UHFFFAOYSA-N 3-[4-(4-chlorophenoxy)phenyl]-5-propan-2-yloxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC(C)C)=NN1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UMDLPUVGLXTSBX-UHFFFAOYSA-N 0.000 description 1
- KWJOHFRWBVBCMS-UHFFFAOYSA-N 3-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-5-propan-2-yloxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC(C)C)=NN1C1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1 KWJOHFRWBVBCMS-UHFFFAOYSA-N 0.000 description 1
- XVFPELAMDKIPMR-UHFFFAOYSA-N 4-(2-oxo-5-propan-2-yloxy-1,3,4-oxadiazol-3-yl)-n-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide Chemical compound O=C1OC(OC(C)C)=NN1C1=CC=C(S(=O)(=O)NC2CC(C)(C)NC(C)(C)C2)C=C1 XVFPELAMDKIPMR-UHFFFAOYSA-N 0.000 description 1
- PVRODASWEQCVJU-UHFFFAOYSA-N 4-(2-oxo-5-propan-2-yloxy-1,3,4-oxadiazol-3-yl)-n-(3,3,5-trimethylcyclohexyl)benzenesulfonamide Chemical compound O=C1OC(OC(C)C)=NN1C1=CC=C(S(=O)(=O)NC2CC(C)(C)CC(C)C2)C=C1 PVRODASWEQCVJU-UHFFFAOYSA-N 0.000 description 1
- LAHZJDRGFUXNKQ-UHFFFAOYSA-N 4-(3,3,5,5-tetramethylcyclohexyl)oxyaniline Chemical compound C1C(C)(C)CC(C)(C)CC1OC1=CC=C(N)C=C1 LAHZJDRGFUXNKQ-UHFFFAOYSA-N 0.000 description 1
- NQVNERSDTNGTAY-UHFFFAOYSA-N 4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-n-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide Chemical compound O=C1OC(OC)=NN1C1=CC=C(S(=O)(=O)NC2CC(C)(C)NC(C)(C)C2)C=C1 NQVNERSDTNGTAY-UHFFFAOYSA-N 0.000 description 1
- IXAQTBBYTXZLGR-UHFFFAOYSA-N 4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-n-(3,3,5-trimethylcyclohexyl)benzenesulfonamide Chemical compound O=C1OC(OC)=NN1C1=CC=C(S(=O)(=O)NC2CC(C)(C)CC(C)C2)C=C1 IXAQTBBYTXZLGR-UHFFFAOYSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- SDVGSYGKNMZAGH-UHFFFAOYSA-N 5-butoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCCCC)=NN1C1=CC=C(OC(F)(F)F)C=C1 SDVGSYGKNMZAGH-UHFFFAOYSA-N 0.000 description 1
- OPUUTKNZIZBSCJ-UHFFFAOYSA-N 5-ethoxy-3-(3-phenoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C1=CC=CC(OC=2C=CC=CC=2)=C1 OPUUTKNZIZBSCJ-UHFFFAOYSA-N 0.000 description 1
- GUZKBNUSIOHJIR-UHFFFAOYSA-N 5-ethoxy-3-(3-phenylmethoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C1=CC=CC(OCC=2C=CC=CC=2)=C1 GUZKBNUSIOHJIR-UHFFFAOYSA-N 0.000 description 1
- NRTFSYXLPQAKOF-UHFFFAOYSA-N 5-ethoxy-3-[3-(4,4,4-trifluorobutoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C1=CC=CC(OCCCC(F)(F)F)=C1 NRTFSYXLPQAKOF-UHFFFAOYSA-N 0.000 description 1
- LFWWBBKWMKBVHM-UHFFFAOYSA-N 5-ethoxy-3-[3-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C1=CC=CC(OC(F)(F)F)=C1 LFWWBBKWMKBVHM-UHFFFAOYSA-N 0.000 description 1
- NTEWAYBSBXOIJK-UHFFFAOYSA-N 5-ethoxy-3-[4-(3,3,5,5-tetramethylcyclohexyl)oxyphenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C(C=C1)=CC=C1OC1CC(C)(C)CC(C)(C)C1 NTEWAYBSBXOIJK-UHFFFAOYSA-N 0.000 description 1
- CIVYKUZVHGQZRG-UHFFFAOYSA-N 5-ethoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC)=NN1C1=CC=C(OC(F)(F)F)C=C1 CIVYKUZVHGQZRG-UHFFFAOYSA-N 0.000 description 1
- MAWQNKAJQQKDTD-UHFFFAOYSA-N 5-methoxy-3-(3-phenoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(OC=2C=CC=CC=2)=C1 MAWQNKAJQQKDTD-UHFFFAOYSA-N 0.000 description 1
- SAHCQJSGRANHHR-UHFFFAOYSA-N 5-methoxy-3-(3-phenylmethoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(OCC=2C=CC=CC=2)=C1 SAHCQJSGRANHHR-UHFFFAOYSA-N 0.000 description 1
- SMPHLQLCFYYSCS-UHFFFAOYSA-N 5-methoxy-3-(3-phenylphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(C=2C=CC=CC=2)=C1 SMPHLQLCFYYSCS-UHFFFAOYSA-N 0.000 description 1
- OAKUUOPHYJPNOP-UHFFFAOYSA-N 5-methoxy-3-(4-morpholin-4-ylsulfonylphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(S(=O)(=O)N2CCOCC2)C=C1 OAKUUOPHYJPNOP-UHFFFAOYSA-N 0.000 description 1
- YAKCIFSNRAIAJM-UHFFFAOYSA-N 5-methoxy-3-(4-phenoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1OC1=CC=CC=C1 YAKCIFSNRAIAJM-UHFFFAOYSA-N 0.000 description 1
- RBGBTTVEPNUTPE-UHFFFAOYSA-N 5-methoxy-3-(4-phenylphenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(C=2C=CC=CC=2)C=C1 RBGBTTVEPNUTPE-UHFFFAOYSA-N 0.000 description 1
- DLXUOLPPMRZJLP-UHFFFAOYSA-N 5-methoxy-3-[3-(3,3,5,5-tetramethylcyclohexyl)oxyphenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(OC2CC(C)(C)CC(C)(C)C2)=C1 DLXUOLPPMRZJLP-UHFFFAOYSA-N 0.000 description 1
- SCJWRTXFSQZXGD-UHFFFAOYSA-N 5-methoxy-3-[3-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(OC(F)(F)F)=C1 SCJWRTXFSQZXGD-UHFFFAOYSA-N 0.000 description 1
- BSEQNRQNIPDQDY-UHFFFAOYSA-N 5-methoxy-3-[3-[(3-methylphenoxy)methyl]phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(COC=2C=C(C)C=CC=2)=C1 BSEQNRQNIPDQDY-UHFFFAOYSA-N 0.000 description 1
- RKQZQAUTGLZFTI-UHFFFAOYSA-N 5-methoxy-3-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(S(=O)(=O)N2CCN(C)CC2)C=C1 RKQZQAUTGLZFTI-UHFFFAOYSA-N 0.000 description 1
- SWWXRDWIAQDLKL-UHFFFAOYSA-N 5-methoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(OC(F)(F)F)C=C1 SWWXRDWIAQDLKL-UHFFFAOYSA-N 0.000 description 1
- UUTYLSKGIIEBRI-UHFFFAOYSA-N 5-phenoxy-3h-1,3,4-oxadiazol-2-one Chemical class O1C(=O)NN=C1OC1=CC=CC=C1 UUTYLSKGIIEBRI-UHFFFAOYSA-N 0.000 description 1
- LBMFAJDBSGCJHE-UHFFFAOYSA-N 5-phenylmethoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(=O)OC(OCC=2C=CC=CC=2)=N1 LBMFAJDBSGCJHE-UHFFFAOYSA-N 0.000 description 1
- DQVHFFZZBLGOAQ-UHFFFAOYSA-N 5-propan-2-yloxy-3-[3-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC(C)C)=NN1C1=CC=CC(OC(F)(F)F)=C1 DQVHFFZZBLGOAQ-UHFFFAOYSA-N 0.000 description 1
- YWTSKTYIULUFJH-UHFFFAOYSA-N 5-propan-2-yloxy-3-[4-(3,3,5,5-tetramethylcyclohexyl)oxyphenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC(C)C)=NN1C(C=C1)=CC=C1OC1CC(C)(C)CC(C)(C)C1 YWTSKTYIULUFJH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- RERONIIVURICED-UHFFFAOYSA-N [4-(3,3,5,5-tetramethylcyclohexyl)oxyphenyl]hydrazine;hydrochloride Chemical compound Cl.C1C(C)(C)CC(C)(C)CC1OC1=CC=C(NN)C=C1 RERONIIVURICED-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- MTMNJFGEKOYMIV-UHFFFAOYSA-N carbonyl dichloride;toluene Chemical compound ClC(Cl)=O.CC1=CC=CC=C1 MTMNJFGEKOYMIV-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- QWIJFFVNJGLTNL-UHFFFAOYSA-N ethyl n-(4-morpholin-4-ylsulfonylanilino)carbamate Chemical compound C1=CC(NNC(=O)OCC)=CC=C1S(=O)(=O)N1CCOCC1 QWIJFFVNJGLTNL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000005171 halobenzenes Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19942354A DE19942354A1 (de) | 1999-09-04 | 1999-09-04 | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln |
| PCT/EP2000/008150 WO2001017981A1 (de) | 1999-09-04 | 2000-08-22 | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung als lipase-hemmer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20021007D0 NO20021007D0 (no) | 2002-02-28 |
| NO20021007L NO20021007L (no) | 2002-02-28 |
| NO323129B1 true NO323129B1 (no) | 2007-01-08 |
Family
ID=7920884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021007A NO323129B1 (no) | 1999-09-04 | 2002-02-28 | Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner, fremgangsmate for frmstilling derav, deres anvendelse som lipasehemmere samt legemiddel inneholdende en slik forbindelse. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6596742B1 (xx) |
| EP (1) | EP1214302B1 (xx) |
| JP (1) | JP2003508522A (xx) |
| KR (1) | KR100723817B1 (xx) |
| CN (1) | CN1152024C (xx) |
| AR (1) | AR032430A1 (xx) |
| AT (1) | ATE253059T1 (xx) |
| AU (1) | AU781330B2 (xx) |
| BR (1) | BR0013765A (xx) |
| CA (1) | CA2383731A1 (xx) |
| CZ (1) | CZ2002772A3 (xx) |
| DE (2) | DE19942354A1 (xx) |
| DK (1) | DK1214302T3 (xx) |
| EE (1) | EE04811B1 (xx) |
| ES (1) | ES2204685T3 (xx) |
| HK (1) | HK1048318B (xx) |
| HR (1) | HRP20020187A2 (xx) |
| HU (1) | HUP0202988A3 (xx) |
| IL (2) | IL148275A0 (xx) |
| MX (1) | MXPA02001834A (xx) |
| NO (1) | NO323129B1 (xx) |
| NZ (1) | NZ517551A (xx) |
| PL (1) | PL197314B1 (xx) |
| PT (1) | PT1214302E (xx) |
| RU (1) | RU2265600C2 (xx) |
| SK (1) | SK285924B6 (xx) |
| TR (1) | TR200200553T2 (xx) |
| WO (1) | WO2001017981A1 (xx) |
| YU (1) | YU10402A (xx) |
| ZA (1) | ZA200201594B (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10102265C1 (de) * | 2001-01-18 | 2002-08-08 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| DE10208986A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase |
| DE10208987A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| US6900233B2 (en) | 2002-02-28 | 2005-05-31 | Aventis Pharma Deutschland Gmbh | Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof |
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
| JP2008515986A (ja) * | 2004-10-13 | 2008-05-15 | ワイス | Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物 |
| EP2178821A2 (en) * | 2007-07-12 | 2010-04-28 | Deviris Inc. | Hormone sensitive lipase modulators and methods of use |
| JP2011507952A (ja) * | 2007-12-27 | 2011-03-10 | バイアル−ポルテラ アンド シーエー，エス．エー． | 医療用途用５−ｏ−置換３−ｎ−フェニル−１、３、４−オキサジアゾロン類 |
| AR074978A1 (es) | 2008-12-23 | 2011-03-02 | Bial Portela & Ca Sa | 3-n-aril-1,3,4-oxadiazolonas 5-o-sustituidas para uso en el tratamiento del dolor y procedimiento de obtencion |
| US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| CN114163351B (zh) * | 2020-09-11 | 2024-01-23 | 江苏优嘉植物保护有限公司 | 噁虫酮中间体2-(2-甲氧基)苯肼甲酸甲酯合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB518042A (en) | 1937-09-15 | 1940-02-15 | Ljungstroms Angturbin Ab | Improvements in elastic fluid turbines of the double rotation type |
| FR2299028A1 (fr) | 1975-02-03 | 1976-08-27 | Rhone Poulenc Ind | Nouvea |
| FR2299328A1 (fr) | 1975-02-03 | 1976-08-27 | Rhone Poulenc Ind | Derives de l'alcoyloxy-5 phenyl-3 oxyde azo |
| US4076824A (en) | 1975-02-03 | 1978-02-28 | Rhone-Poulenc Industries | Anthelmintic oxadiazolinone derivatives |
| DK156439C (da) | 1980-09-15 | 1990-01-22 | Shell Int Research | 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer |
| DE3267258D1 (en) | 1981-06-15 | 1985-12-12 | Shell Int Research | 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates |
| JPS60115502A (ja) * | 1983-11-28 | 1985-06-22 | Mitsubishi Chem Ind Ltd | 殺虫剤 |
| US5236939A (en) | 1989-09-23 | 1993-08-17 | Bayer Aktiengesellschaft | Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites |
| DE3931843A1 (de) | 1989-09-23 | 1991-04-04 | Bayer Ag | Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
-
1999
- 1999-09-04 DE DE19942354A patent/DE19942354A1/de not_active Withdrawn
-
2000
- 2000-08-22 YU YU10402A patent/YU10402A/sh unknown
- 2000-08-22 EP EP00962346A patent/EP1214302B1/de not_active Expired - Lifetime
- 2000-08-22 SK SK301-2002A patent/SK285924B6/sk not_active IP Right Cessation
- 2000-08-22 WO PCT/EP2000/008150 patent/WO2001017981A1/de active IP Right Grant
- 2000-08-22 JP JP2001521728A patent/JP2003508522A/ja active Pending
- 2000-08-22 DE DE50004274T patent/DE50004274D1/de not_active Expired - Lifetime
- 2000-08-22 KR KR1020027002775A patent/KR100723817B1/ko not_active IP Right Cessation
- 2000-08-22 AU AU74112/00A patent/AU781330B2/en not_active Ceased
- 2000-08-22 AT AT00962346T patent/ATE253059T1/de not_active IP Right Cessation
- 2000-08-22 NZ NZ517551A patent/NZ517551A/en unknown
- 2000-08-22 MX MXPA02001834A patent/MXPA02001834A/es active IP Right Grant
- 2000-08-22 BR BR0013765-0A patent/BR0013765A/pt not_active Application Discontinuation
- 2000-08-22 CA CA002383731A patent/CA2383731A1/en not_active Abandoned
- 2000-08-22 EE EEP200200109A patent/EE04811B1/xx not_active IP Right Cessation
- 2000-08-22 PT PT00962346T patent/PT1214302E/pt unknown
- 2000-08-22 TR TR2002/00553T patent/TR200200553T2/xx unknown
- 2000-08-22 IL IL14827500A patent/IL148275A0/xx active IP Right Grant
- 2000-08-22 ES ES00962346T patent/ES2204685T3/es not_active Expired - Lifetime
- 2000-08-22 CN CNB008121346A patent/CN1152024C/zh not_active Expired - Fee Related
- 2000-08-22 PL PL353214A patent/PL197314B1/pl not_active IP Right Cessation
- 2000-08-22 CZ CZ2002772A patent/CZ2002772A3/cs unknown
- 2000-08-22 HU HU0202988A patent/HUP0202988A3/hu unknown
- 2000-08-22 RU RU2002108509/04A patent/RU2265600C2/ru not_active IP Right Cessation
- 2000-08-22 DK DK00962346T patent/DK1214302T3/da active
- 2000-09-01 AR ARP000104589A patent/AR032430A1/es not_active Application Discontinuation
- 2000-09-05 US US09/655,373 patent/US6596742B1/en not_active Expired - Lifetime
-
2002
- 2002-02-20 IL IL148275A patent/IL148275A/en not_active IP Right Cessation
- 2002-02-26 ZA ZA200201594A patent/ZA200201594B/en unknown
- 2002-02-28 NO NO20021007A patent/NO323129B1/no not_active IP Right Cessation
- 2002-02-28 HR HR20020187A patent/HRP20020187A2/hr not_active Application Discontinuation
-
2003
- 2003-01-23 HK HK03100568.9A patent/HK1048318B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323483B1 (no) | Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase samt fremgangsmate for fremstilling av forbindelsene. | |
| US8202859B2 (en) | Heterocyclic sulfonamides | |
| NO323129B1 (no) | Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner, fremgangsmate for frmstilling derav, deres anvendelse som lipasehemmere samt legemiddel inneholdende en slik forbindelse. | |
| NO321664B1 (no) | N-heterosykliske derivater som NOS-inhibitorer | |
| WO1999046244A1 (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| US20020165398A1 (en) | Modulators of protein tyrosine phosphatases (PTPases) | |
| WO2007146914A1 (en) | Ghrelin modulating compounds | |
| NO153135B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk virksomme n-(fenoksyalkyl)-imidazolderivater | |
| JP2003525931A6 (ja) | 置換された３−フェニル−５−アルコキシ−１，３，４−オキサジアゾール−２−オンおよびホルモン感受性リパーゼを阻害するためのその使用 | |
| US20110112158A1 (en) | Benzisoxazole analogs as glycogen synthase activators | |
| US20030236288A1 (en) | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | |
| US6900233B2 (en) | Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof | |
| DE10010968A1 (de) | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen | |
| EP1062204A1 (en) | Modulators of protein tyrosine phosphatases (ptpases) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |